Biotech · Private company · San Diego, CA, US
Electronic Biosciences, Inc.
Track this companyFree. Adds Electronic Biosciences, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards10
- Next-Generation Oncoproteomic Sequencing and Precision ProfilingFiscal year 2026 · $418.9KNIH RePORTER 1R21CA304932-01A1 · fetched Nov 12, 2026
- Enabling Protein Sequencing Through Friction-Mediated Nanopore TransportFiscal year 2026 · $466.3KNIH RePORTER 1R21GM165253-01 · fetched Nov 12, 2026
- High-Fidelity Nanopore Sequencing of CGG Repeats and Methylation in the FMR1 GeneFiscal year 2026 · $472.7KNIH RePORTER 1R21HD121871-01 · fetched Nov 12, 2026
- High-Resolution Pseudouridine and m6A Sequencing Through Advanced Nanopore Adduct AnalysisFiscal year 2025 · $350KNIH RePORTER 1R41GM157757-01 · fetched Nov 12, 2026
- Rapid Fingerstick Diagnostics for Opioid and Stimulant Use DisordersFiscal year 2025 · $386.5KNIH RePORTER 1R43DA063260-01 · fetched Nov 12, 2026
- Direct Proteolytic Machine Assessments for Unfolding and Sequencing ProteinsFiscal year 2025 · $350KNIH RePORTER 1R43GM159820-01 · fetched Nov 12, 2026
- SpinSeqFiscal year 2025 · $383.5KNIH RePORTER 1R43HG014419-01 · fetched Nov 12, 2026
- Fourth-Generation Nanopore-Assisted Sequencing for Advanced Oncological AnalysesFiscal year 2024 · $400KNIH RePORTER 1R43CA295247-01 · fetched Nov 12, 2026
- Re-Reading RNA to Obtain High AccuracyFiscal year 2024 · $347KNIH RePORTER 1R43HG012858-01A1 · fetched Nov 12, 2026
- Next-Generation Cardiovascular Risk Assessments Via State-Of-The-Art Lipoprotein CharacterizationFiscal year 2024 · $400KNIH RePORTER 1R43HL174365-01A1 · fetched Nov 12, 2026